Edition:
United Kingdom

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

60.96USD
14 Dec 2018
Change (% chg)

$-1.19 (-1.91%)
Prev Close
$62.15
Open
$61.48
Day's High
$62.31
Day's Low
$60.51
Volume
103,847
Avg. Vol
128,729
52-wk High
$73.83
52-wk Low
$42.71

Latest Key Developments (Source: Significant Developments)

Emergent BioSolutions - Co's Adapt Subsidiaries And Opiant Filed Complaint
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS SAYS CO'S ADAPT SUBSIDIARIES AND OPIANT FILED COMPLAINT FOR PATENT INFRINGEMENT AGAINST PERRIGO IN U.S. COURT - SEC FILING.EMERGENT BIOSOLUTIONS - PATENT INFRINGEMENT COMPLAINT FILED ARISING FROM PERRIGO'S ANDA FILING WITH FDA FOR GENERIC VERSION OF NARCAN NASAL SPRAY 4MG/SPRAY.  Full Article

Cepi Awards $36 Million Contract To Profectus Biosciences And Emergent Biosolutions
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Emergent BioSolutions Inc ::CEPI AWARDS CONTRACT WORTH UP TO $36 MILLION TO PROFECTUS BIOSCIENCES AND EMERGENT BIOSOLUTIONS TO DEVELOP LASSA VIRUS VACCINE.COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS - AS PER CONTRACT, PROFECTUS WILL RECEIVE DEVELOPMENT FUNDING FROM CEPI FOR ADVANCING ITS LASSA VIRUS VACCINE.  Full Article

Emergent Biosolutions Inc Files For Potential Mixed Shelf Offering
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING.  Full Article

Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer​
Monday, 26 Mar 2018 

March 26 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY.EMERGENT BIOSOLUTIONS INC - ‍APPOINTED RICHARD S. LINDAHL AS COMPANY'S NEW EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.EMERGENT BIOSOLUTIONS INC - PROMOTED ROBERT G. KRAMER SR. TO NEWLY-CREATED POSITION OF PRESIDENT AND CHIEF OPERATING OFFICER​.EMERGENT BIOSOLUTIONS - ‍LINDAHL MOST RECENTLY SERVED AS CFO AT CEB INC​.  Full Article

Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Emergent Biosolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK.SEES FY 2017 REVENUE $555 MILLION TO $560 MILLION.SEES Q1 2018 REVENUE $145 MILLION TO $160 MILLION.SEES FY 2017 REVENUE UP 14 PERCENT.- FOR FULL YEAR 2017, ANTICIPATES CASH AND CASH EQUIVALENTS AT YEAR END OF ABOUT $180 MILLION.- SEES 2018 TOTAL REVENUES FROM $715 MILLION TO $755 MILLION.SEES 2018 ADJUSTED NET INCOME $110 MILLION TO $125 MILLION.- FULL YEAR 2017 ADJUSTED NET INCOME IS ANTICIPATED TO BE $92 TO $96 MILLION.- FOR FULL YEAR 2017, ANTICIPATES NET INCOME OF $80 TO $84 MILLION.SEES 2018 NET INCOME $95 MILLION TO $110 MILLION.FY2017 REVENUE VIEW $547.9 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $659.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Emergent Biosolutions Awarded Department Of National Defence Contract
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Emergent Biosolutions Inc ::EMERGENT BIOSOLUTIONS AWARDED DEPARTMENT OF NATIONAL DEFENCE CONTRACT TO SUPPLY ANTHRASIL TO THE CANADIAN GOVERNMENT.HAS BEEN AWARDED CONTRACT BY DEPARTMENT OF NATIONAL DEFENCE VALUED AT ABOUT $8 MILLION TO DELIVER ANTHRASIL TO CANADIAN GOVERNMENT.  Full Article

Emergent Biosolutions reports third quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Emergent Biosolutions Inc :Emergent Biosolutions reports third quarter and nine months 2017 financial results; raises calendar year 2017 guidance.Q3 earnings per share $0.68.Q3 revenue $149.4 million versus I/B/E/S view $124.6 million.Q3 earnings per share view $0.41 -- Thomson Reuters I/B/E/S.Emergent Biosolutions Inc sees FY 2017 ‍total revenues $540 million to $560​ million.Emergent Biosolutions Inc sees ‍FY 2017 net income $70 million to $80​ million.Emergent Biosolutions Inc sees FY 2017 ‍adjusted net income $85 million to $95​ million.  Full Article

Emergent-Valneva Zika vaccine clears early trial

Nov 19 A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.